Zentalis Pharmaceuticals (ZNTL) Return on Capital Employed (2020 - 2026)

Zentalis Pharmaceuticals' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 61.51% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 224.0% year-over-year to 61.51% in Q1 2026; TTM through Mar 2026 was 61.51%, a 224.0% decrease from a year earlier, with the FY2025 full-year figure at 47.3%, down 367.0% from the prior year.
• Return on Capital Employed declined to 61.51% in Q1 2026 per ZNTL's latest filing, from 56.27% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 45.25% in Q3 2022 and bottomed at 61.51% in Q1 2026.
• The 5-year median for Return on Capital Employed is 53.04% (2022), against an average of 53.45%.
• Across the five-year window, Return on Capital Employed soared 1992 bps in 2022 and tumbled 1239 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 47.59% in 2022, then retreated by 26 bps to 59.98% in 2023, then gained by 18 bps to 49.31% in 2024, then declined by 14 bps to 56.27% in 2025, then retreated by 9 bps to 61.51% in 2026.
• Per Business Quant, the three latest ZNTL Return on Capital Employed figures stand at 61.51% (Q1 2026), 56.27% (Q4 2025), and 54.67% (Q3 2025).